This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository: https://orca.cardiff.ac.uk/id/eprint/143662/

This is the author’s version of a work that was submitted to / accepted for publication.

Citation for final published version:

Hasmi, Laila, Pries, Lotta-Katrin, ten Have, Margreet, de Graaf, Ron, van Dorsselaer, Saskia, Bak, Maarten, Kenis, Gunter, Richards, Alexander, Lin, Bochao D., O'Donovan, Michael C. ORCID: https://orcid.org/0000-0001-7073-2379, Luykx, Jurjen J., Rutten, Bart P.F., Guloksuz, Sinan and van Os, Jim 2021. What makes the psychosis ‘clinical high risk’ state risky: psychosis itself or the co-presence of a non-psychotic disorder? Epidemiology and Psychiatric Sciences 30, e53. 10.1017/S204579602100041X

Publishers page: http://dx.doi.org/10.1017/S204579602100041X
<http://dx.doi.org/10.1017/S204579602100041X>

Please note:

Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher’s version if you wish to cite this paper.

This version is being made available in accordance with publisher policies. See http://orca.cf.ac.uk/policies.html for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders.
What makes the psychosis ‘clinical high risk’ state risky: psychosis itself or the co-presence of a non-psychotic disorder?

Laila Hasmi1, Lotta-Katrin Pries1, Margreet ten Have2, Ron de Graaf2, Saskia van Dorselaer2, Maarten Bak1,3, Gunter Kenis1, Alexander Richards4, Bochao D. Lin5,6, Michael C. O’Donovan4, Jurjen J. Luykx5,7,9, Bart P.F. Rutten1, Sinan Guloksuz1,9 and Jim van Os1,8,10

1Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University Medical Centre, Maastricht, the Netherlands; 2Department of Epidemiology, Netherlands Institute of Mental Health and Addiction, Utrecht, The Netherlands; 3FACT, Mondriaan Mental Health, Maastricht, Netherlands; 4MRC Centre for Neuropsychiatric Genetics & Genomics, Division of Psychological Medicine & Clinical Neurosciences, Cardiff University, Cardiff, United Kingdom; 5Department of Translational Neuroscience, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands; 6Department of Neurology, Brain Centre Rudolf Magnus, University Medical Centre Utrecht, Utrecht, the Netherlands; 7GGNet Mental Health, Apeldoorn, The Netherlands; 8Department of Psychiatry, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands; 9Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA and 10Department of Psychotherapy, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, UK

Abstract

Aims. Although attenuated psychotic symptoms in the psychosis clinical high-risk state (CHR-P) almost always occur in the context of a non-psychotic disorder (NPD), NPD is considered an undesired ‘comorbidity’ epiphenomenon rather than an integral part of CHR-P itself. Prospective work, however, indicates that much more of the clinical psychosis incidence is attributable to prior mood and drug use disorders than to psychosis clinical high-risk states per se. In order to examine this conundrum, we analysed to what degree the ‘risk’ in CHR-P is indexed by co-present NPD rather than attenuated psychosis per se.

Methods. We examined the incidence of early psychotic experiences (PE) with and without NPD (mood disorders, anxiety disorders, alcohol/drug use disorders), in a prospective general population cohort (n = 6123 at risk of incident PE at baseline). Four interview waves were conducted between 2007 and 2018 (NEMESIS-2). The incidence of PE, alone (PE-only) or with NPD (PE + NPD) was calculated, as were differential associations with schizophrenia polygenic risk score (PRS-Sz), environmental, demographical, clinical and cognitive factors.

Results. The incidence of PE + NPD (0.37%) was lower than the incidence of PE-only (1.04%), representing around a third of the total yearly incidence of PE. Incident PE + NPD was, in comparison with PE-only, differentially characterised by poor functioning, environmental risks, PRS-Sz, positive family history, prescription of antipsychotic medication and (mental) health service use.

Conclusions. The risk in ‘clinical high risk’ states is mediated not by attenuated psychosis per se but specifically the combination of attenuated psychosis and NPD. CHR-P/APS research should be reconceptualised from a focus on attenuated psychotic symptoms with exclusion of non-psychotic DSM-disorders, as the ‘pure’ representation of a supposedly homotypic psychosis risk state, towards a focus on poor-outcome NPDs, characterised by a degree of psychosis admixture, on the pathway to psychotic disorder outcomes.

Introduction

There is considerable interest in the psychosis clinical High-Risk state (CHR-P) as a paradigm to identify the risk factors, mechanisms and early intervention potential associated with the onset of psychotic disorder (Fusar-Poli et al., 2020). CHR-P is defined mainly by the presence of attenuated psychotic symptoms which, accordingly, represent the central part of the definition of attenuated psychosis syndrome (APS) in (the appendix of) DSM-5 (Tsuang et al., 2013).

Although some have proposed that the CHR-P/APS construct may be valid (Woods et al., 2009; Salazar de Pablo et al., 2020), others point to epistemic, conceptual and methodological limitations surrounding different aspects of CHR-P research (van Os and Guloksuz, 2017; Ajnakina et al., 2018; Moritz et al., 2019). Clarification of these issues is urgently required given increasingly large-scale research projects based on the CHR-P paradigm.
One major validity issue is related to non-psychotic ‘comorbidity’ in CHR-P research. Non-psychotic ‘comorbidity’ does not form part of the CHR-P/APS construct. Rather, it is treated as an exclusion factor in the criteria for APS and CHR-P through formulations like ‘attenuated psychotic symptoms are not explained better by another DSM disorder’ (Salazar de Pablo et al., 2020). Nevertheless, the samples collected in the context of CHR-P research invariably show that the vast majority of individuals (around 80%) have a diagnosis of non-psychotic disorder (NPD). A recent systematic review including 56 studies showed that 49% presented with comorbid depressive disorders, 22% with bipolar disorder, 38% with anxiety disorders and 20% with substance use disorders (sum of percentages is greater than 100 due to comorbidity) (Salazar de Pablo et al., 2020).

This state of affairs represents an unacceptable conundrum: according to definitions, CHR-P/APS can only include attenuated psychotic symptoms that are not ‘better explained’ by another DSM-disorder – yet the vast majority of individuals meeting CHR-P/APS criteria present with another DSM-disorder. The likely explanation for this apparent paradox is mis-specification of the CHR-P/APS construct itself. Thus, the co-presence of NPD in CHR-P/APS samples may not be an ‘unwelcome’ epiphenomenon but rather represent an integral part of the CHR-P/APS construct itself. NPD may be what mediates the ‘risk’ in the concept of CHR-P and represent the mechanism for the relatively poor outcome over time associated with the CHR-P/APS state, whether or not ‘transition’ took place (Lin et al., 2011). While this explanation initially may not seem straightforward, it is from the perspective of population-based sampling. Research shows that individuals with mental health difficulties typically experience multiple diagnoses over the life course, often beginning with NPDs (Plana-Ripoll et al., 2019), whereas the artificially ‘pure’ CHR-P samples advance a competing, but incorrect, notion that psychosis is somehow inherently homotypic and therefore inconsistent with transdiagnostic symptoms (van Os and Guloksuz, 2017; Raballo and Poletti, 2019). However, population-based research shows that a prior diagnosis of mood disorder, neurotic disorder, eating disorder and substance use disorder – or basically any diagnosis outside the schizophrenia spectrum increases the risk of a later diagnosis of schizophrenia 10–20 fold (Plana-Ripoll et al., 2019) or 5-fold (Weiser et al., 2001). Indeed, recent prospective work showed that much more of the clinical psychosis incidence is attributable to prior mood and drug use disorders than to psychosis clinical high-risk states (Guloksuz et al., 2020).

One of the weaknesses of CHR-P sampling frames is that they are based on non-epidemiological opportunity sampling of selected help-seeking individuals with a NPD, yielding sample-specific results that are neither representative (Ajnakina et al., 2018) nor generalisable (van Os and Guloksuz, 2017). Indeed, ‘transitions’ in these individuals largely arise as a function of risk enrichment strategies embedded in specific sampling procedures (Fusar-Poli et al., 2016), limiting their use as a model of the onset of psychosis in the general population. Population-based cohort studies, however, can address the dynamics of attenuated psychotic symptoms and the role of NPD over time in representative samples (van Os et al., 2021). These studies have shown that the co-presence of NPD, present in around 50% of individuals with attenuated psychotic symptoms (Van Os et al., 2000; Jeppesen et al., 2015), is a crucial distinguishing factor in relation to aetiological load, clinical relevance and outcome (Hanssen et al., 2005; Kaymaz et al., 2007; van Rossum et al., 2011; Wigman et al., 2012; Pries et al., 2018; Radhakrishnan et al., 2019). Also, attenuated psychotic symptoms in isolation are either not (Jones et al., 2016; van Os et al., 2020), negatively (Hatzimanolis et al., 2018) or weakly (Pain et al., 2018; Legge et al., 2019) associated with polygenic risk for schizophrenia (PRS-SZ), but tend to show progressively stronger association with PRS-SZ in combination with more environmental exposure, more affective comorbidity and more clinical relevance (Hatzimanolis et al., 2018; Guloksuz et al., 2019; Guloksuz et al., 2020). PE may be associated with subjective (Koyanagi et al., 2018) or objective cognitive alterations (Niauchou et al., 2013; Gur et al., 2014; Rossler et al., 2015); there is evidence, however, that the association with cognitive alterations is dependent on the degree of comorbid non-psychotic psychopathology (Reininghaus et al., 2019). Indeed, recent follow-back studies from representative incidence samples of psychotic disorder have shown that the origins of psychotic disorder can be traced to NPDs, the severest of which develop a degree of psychosis admixture over time (Cupo et al., 2021). Indeed, studies using prospective approaches show that nonpsychotic syndromes are frequently observed not just alongside psychotic experiences (PE)/symptoms, but even before them (Hafner et al., 1999; Shah et al., 2019).

Here, we investigated the clinical significance of the co-presence of NPD in first-onset PE. To this end we calculated, for the first time, the incidence rate of PE, alone (PE-only) and as a function of co-presence of NPD (PE + NPD - mood disorders, anxiety disorders and alcohol/drug use disorders) in a risk set of people without PE at baseline. We also analysed the differential impact of relevant clinical, aetiological, cognitive and demographic factors on the incidence of PE-alone and PE + NPD.

We hypothesised that a minority of people with incident PE would have co-presence of NPD, and that clinical, demographic, aetiological and cognitive factors, known to be associated with psychotic disorder, would display stronger and/or qualitatively different associations with the incident PE + NPD phenotype in comparison with the PE-only phenotype.

**Method**

**Sample**

The four waves of the Netherlands Mental Health Survey and Incidence Study-2 (NEMESIS-2) were used (n = 6646 at baseline or T0). NEMESIS-2 was conducted over the period 2007–2018 to study the prevalence, incidence, course, and consequences of mental disorders in a representative sample of the Dutch general population (for description see online Supplementary material).

**Sample risk set**

Individuals, with confirmed psychosis at baseline and therefore not at risk anymore of developing incident psychosis, were not included in the risk set. Thus, individuals with a diagnosis of any psychotic disorder according to the DSM-IV (n = 43) were excluded from analysis. Also, those who had PE present in the year before T0 were excluded (n = 480), leaving 6123 participants at T0 considered at risk of developing incident PE. Individuals who had PE in the past, but more than 1 year before baseline and not in the year before baseline, were considered at risk of developing new incident PE and included in the risk set. The 6123 individuals thus included in the risk set yielded 19,115 observations over T0-T3. Of the 6123 individuals at T0, 4930...
remained at T1 after a mean follow-up of 3.02 years; 4314 remained at T2, after a mean follow-up of 6.01 years; and 3748 remained at T3, after a mean follow-up of 9.04 years.

A planned sensitivity analysis was carried out with a more restricted risk set, excluding all participants with any PE at baseline (n = 5565 at baseline, total sample n = 17 282).

Given the age range of the sample (18–65 years at baseline), another sensitivity analysis was conducted in order to examine if results would be similar when restricted to the sample aged 18–35 at baseline (n = 1439, 26%), the age range during which most psychosis onset takes place.

As the definition of non-psychotic diagnoses (NPD) included drug abuse and dependence, a further sensitivity analysis of the association with cannabis use was conducted excluding individuals with drug abuse or dependence from the definition of NPD.

Finally, for the measures split at the xth percentile (social functioning, digit span, childhood trauma, PRS), which may be considered arbitrary, we included sensitivity analyses with continuous scores.

**Assessment of NPDS**

The following CIDI, version 3.0, non-psychotic diagnoses (NPD) were assessed, as described in the online Supplementary material: major depression, dysthymia, bipolar disorder, panic disorder, agoraphobia, social phobia, specific phobia, GAD, alcohol abuse and dependence, drug abuse and dependence. The analyses thus focused on people who developed incident PE over the period of observation, either alone (PE-only) or in the co-presence of NPD (PE + NPD).

**Assessment of PE**

In NEMESIS-2, a psychosis add-on instrument based on the G section of previous CIDI-versions was included. This add-on instrument consists of 20 psychotic symptoms corresponding to the symptoms assessed in a previous population survey in the Netherlands, NEMESIS, the precursor of NEMESIS-2 (Bijl et al., 1998; de Graaf et al., 2010). Detailed descriptions of the specific PE items can be found in previous work using NEMESIS (Smeets et al., 2013) and NEMESIS-2 (van Nierop et al., 2012) and are described in the online supplementary material. PE was dichotomised consistent with previous work in NEMESIS and NEMESIS-2 (van Rossum et al., 2011; Pries et al., 2018; Radhakrishnan et al., 2019). Presence of delusions was defined as having at least one delusion endorsed and presence of hallucinations was similarly defined (online Supplementary material).

**Exposure variables**

We examined 17 exposures associated with psychotic disorder. Dichotomous measures of exposure were created at the 75th percentile, unless a previous publication had used another cut-off in which case this was used for reasons of consistency (see below).

**Working memory performance**

The digit-span task, subtest of the Wechsler Adult Intelligence Scale (WAIS-III) (Wechsler, 1997), was performed by participants at T1 and T3. The digit-span task was split into two sections, a forward (six items) and backward (six items) task condition. The sum score at T1 and T3 was computed, and the average of these two values was considered as a person-level indicator of cognitive ability for all waves. In the analysis, a dichotomised variable was used, with cut-off at the 75th percentile, the highest value indicating poorer performance.

**Jumping to conclusion bias (JTC bias)**

The presence or absence of a JTC bias was assessed at T2, utilising the beads task (online Supplementary material) and used as a person-level, time-invariant dichotomous variable in the analyses.

**Childhood adversity**

Childhood adversity was assessed at T0 using a questionnaire based on the NEMESIS trauma questionnaire (de Graaf et al., 2010), and used as a dichotomous variable in the analyses (online Supplementary material).

**Cannabis use**

Cannabis use was assessed with the section substance use disorders of the CIDI at each interview wave and used as a dichotomous variable in the analyses (online Supplementary material).

**Urbanicity**

The degree of exposure to the urban environment until the age of 16 years, was assessed at T0 and used as a dichotomous variable in the analyses (online Supplementary material).

**Family history**

Family history was assessed as a person-level characteristic in two stages, as described previously (Radhakrishnan et al., 2019) and detailed in the online Supplementary material.

**Hearing impairment**

Hearing impairment was assessed during the face-to-face interview at all interview waves, by asking whether participants had experienced deafness or serious hearing impairment in the past 12 months. Ratings were yes (1) or no (0).

**Social functioning**

The evaluation of social functioning covered the past 4 weeks, and was assessed at each interview wave, applying a 2-item, 6-point subscale of the Medical Outcomes Study Short-form Health Survey (MOS SF-36) (Stewart et al., 1988; Ware and Sherbourne, 1992), with a Cronbach’s alpha of 0.78. Impaired social functioning includes issues in one’s normal social activities as a result of somatic or emotional troubles. It was used as a binary variable in the analysis, dichotomised around the 75th percentile.

**Service use for mental problems**

Use of any form of care or specific mental health care, as well as use of antipsychotic medication, was assessed at each interview wave (online Supplementary material).

**Perceived status gap**

The perceived status gap is a dichotomous variable indicating the difference between the subjective desired and actual social status (online Supplementary material).

**Adult stressful life events**

Based on the ‘Brugha Life events section’ (Brugha et al., 1985), participants were asked at each interview whether they experienced one of nine life events within the last 12 months. Examples of items are serious sickness, death of family member...
or close friend, and serious financial problems. A dichotomous exposure was created around at least one life event in the last year.

**Polygenic risk score for schizophrenia**

The PRS-SZ were created from best-estimate genotypes at six different p-thresholds (0.5, 0.1, 0.05, 5\times10^{-3}, 5\times10^{-5}, 5\times10^{-8}), as described in the online Supplementary material. For our primary analyses, we used the p-threshold of <0.05, as this threshold explained most variation in liability in the Psychiatric Genomics Consortium analysis (Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2014) and was shown to perform well for the current phenotype of SF-36 mental health (Pries et al., 2019). Further details on the genotyping procedure and polygenic risk scores calculation, as described previously (Pries et al., 2018; Guloksuz et al., 2020), are provided in the supplement. Consistent with previous analyses, statistical analyses with PRS-SZ were adjusted for three principal components (Pries et al., 2020).

Material for DNA analysis of sufficient quality, and hence for polygenic risk scores calculation, was available for 3104 individuals (47%) at T0 (online Supplementary material). Excluding individuals who at interview has been assessed as member of an ethnic minority (online Supplementary material), given lack of generalisability of polygenic risk scores to this group, and individuals diagnosed with a psychotic disorder, left 3037 for PRS calculation, of whom 2836 remained in the risk set for incidence analysis as defined below. These 2836 with polygenic risk scores yielded 9737 observations over the four interview waves. Values for important and time-varying clinical, environmental, cognitive and demographic variables were very similar in a comparison between the 9737 observations in the subsample with polygenic risk scores data available and the 10 238 observations in the risk set with missing polygenic risk scores data (online Supplementary Table 2).

**Demographic factors**

Demographic variables included were sex (0 = male, 1 = female), age in years and dichotomous ethnic minority status (Moroccan, Turkish, Surinamese, Antillean, Indonesian or other non-Western ethnic group). Age was analysed as a dichotomous variable, defining a younger age group encompassing the range most at risk of onset of psychotic disorder (18 to 35 years, 24% at baseline) versus the older group.

**Analysis**

**PE-only and PE + NPD groups**

Two outcomes were defined to test the hypotheses regarding PE in relation to the context of NPD. The first was defined as PE without NPD, the second as PE in the co-presence of NPD. For each group we established (i) the incidence and (ii) associations with cognitive, clinical, demographic and aetiological variables, expressed as hazard ratio’s (HR) and their 95% confidence intervals (CI) from Cox proportional hazards regression.

**Analysis of incidence and predictors of incidence**

The STSET command was used to obtain the format of survival data in Stata, guiding treatment of time-varying and fixed independent variables in the analyses. Incidence was calculated using failures in single-failure per subject data (i.e. one single event was defined as failure, with a single record per subject), divided by the number of person-years. Incidence was calculated using the Stata STSUM routine. Cox regression was done using the Stata STCOX routine. The proportional-hazards assumption was tested with the Stata ESTAT PHTEST routine, which detected no violations.

**Results**

**Sample characteristics**

Mean age of the 6123 participants in the risk set at T0 was 44.4 years (s.d. = 12.5, range 18–68), 55% were female. More than a third (37%) had a higher professional education or university degree, 32% had completed up to higher secondary education, 27% up to lower secondary education and 5% had completed primary education only; 74% were married or cohabiting; 20% lived alone; 70% were in paid employment; 7% pertained to an ethnic minority group.

**Incidence of PE-only and PE + NPD combinations**

The incidence of PE-only was 1.04% (Table 1). The incidence of NPD and PE combined was 0.37%, or around 25% of the total PE incidence [(0.37/ (1.04 + 0.37)] (Table 1).

**PE-only and PE + NPD associations with clinical, demographic, cognitive and aetiological factors**

The distribution of clinical, demographic, cognitive and aetiological factors tended to be different across the PE-only and PE + NPD groups, in comparison with the remainder of the sample, for most variables (Table 2). online Supplementary Table 3 displays the pattern of time-varying and time-constant exposures for the PE-only and PE + NPD incidence analysis. Online Supplementary Table 4 details the person-years, failures and incidence rates of PE-only and PE + NPD as a function of the various binary demographic, clinical, aetiological and cognitive risk factors. Hazard ratios are presented in Table 3 and the pattern of results is summarised in Fig. 1.

The pattern of results, as displayed in Table 3 and Fig. 1, was that most hazard ratio effect sizes were much higher for PE + NPD as compared to PE-only. Perceived status gap, low social functioning, care use, antipsychotic use, childhood adversity, life events, PRS, urbanicity and family history discriminated between PE-only and PE + NPD, as evidenced by non-overlapping confidence intervals of the hazard ratios. In addition, suggestive differences (large and significant hazard ratio in PE + NPD; small and non-significant hazard ratio in PE-only) were apparent for cannabis use and ethnic minority status. The suggestive differential association with cannabis use remained after excluding individuals with drug abuse/dependence from the definition of NPD (PE-only: odds ratio (OR) = 1.83, 95% CI: 0.59–5.69; PE + NPD: OR = 6.27, 95% CI: 1.99–19.76).

The sensitivity analysis with the more restricted risk set, excluding all participants with PE at baseline revealed results that were very similar to the results in Table 3, quantitatively and qualitatively (online Supplementary Table 5). The other sensitivity analysis restricted to individuals aged 18–35 at baseline (n = 1439, 26%) similarly revealed a very similar pattern of results (online Supplementary Fig. 2). Finally, for the measures split at the xth percentile (social functioning, digit span, childhood trauma, PRS) results for the continuous exposures yielded similar discrimination between PE-only and PE + NPD for
that PE-NPD is integral to transitions to psychosis, in line with recent prospective work showing that much more of the clinical psychosis incidence is attributable to prior mood and drug use disorders than to psychosis clinical high-risk states (Guloksuz et al., 2020). Other arguments are, first, clinical face validity, given that the finding of differential associations with poor functioning, use of mental health care and psychotropic medications represents actual clinical status differentiation, which is a necessary requirement for later poor outcome. Second, differential associations with greater aetiological loading (childhood adversity, cannabis use, polygenic score) are associated with poorer outcome of psychotic states (Van Os et al., 1998; Grech et al., 2005; Jonas et al., 2019). Third, prospective studies have shown greater risk of transition and other poorer outcomes of psychosis risk states for many of the factors differentiating between PE-only and PE + NPD in this study including childhood adversity and cannabis use (van Nierop et al., 2013; Trotta et al., 2015; Kraan et al., 2018), non-psychotic comorbidity (Hanssen et al., 2020; Rutigliano et al., 2018).

**Table 1. Incidence of PE, either alone or co-present with NPDs**

| Incident experience | Participants | Time at risk (years) | Number of incident cases | Incidence % |
|---------------------|--------------|----------------------|--------------------------|-------------|
| PE-only             | 4930         | 37,898.1             | 395                      | 1.04        |
| PE + NPD            | 4930         | 38,721.3             | 142                      | 0.37        |

PE: psychotic experiences; NPD: non-psychotic disorder.

*The total number of person-years, derived from the sum of persons and the length of their individual follow-ups, in years.

**Table 2. Distribution of risk factors (proportions) as a function of PE, either alone or in combination with NPD across T0, T1, T2 and T3 repeated observations (6123 individuals yielding 19,115 observations)**

| Binary exposure         | No PE (n = 18,476) (proportion) | PE-only (n = 462) (proportion) | PE + NPD (n = 177) (proportion) | Total (n = 19,115) (proportion) | Total exposed (n) |
|-------------------------|---------------------------------|--------------------------------|---------------------------------|---------------------------------|------------------|
| Young age group         | 0.16                            | 0.16                           | 0.18                            | 0.16                            | 3045             |
| Female sex              | 0.54                            | 0.60                           | 0.66                            | 0.55                            | 10,458           |
| Perceived status gap    | 0.18                            | 0.27                           | 0.53                            | 0.18                            | 3487             |
| Low social functioning  | 0.32                            | 0.42                           | 0.77                            | 0.33                            | 6217             |
| Any care                | 0.11                            | 0.15                           | 0.64                            | 0.12                            | 2233             |
| Mental health care      | 0.06                            | 0.07                           | 0.42                            | 0.06                            | 1193             |
| Antipsychotic use       | 0.02                            | 0.01                           | 0.04                            | 0.02                            | 74               |
| Cannabis use            | 0.02                            | 0.01                           | 0.04                            | 0.02                            | 348              |
| Childhood adversity     | 0.18                            | 0.26                           | 0.49                            | 0.18                            | 3487             |
| Life events             | 0.47                            | 0.55                           | 0.67                            | 0.47                            | 8980             |
| Ethnic minority         | 0.07                            | 0.08                           | 0.16                            | 0.07                            | 1363             |
| Hearing impairment      | 0.03                            | 0.06                           | 0.06                            | 0.03                            | 549              |
| Urbanicity <16 years    | 0.39                            | 0.33                           | 0.50                            | 0.39                            | 7377             |
| Family history          | 0.58                            | 0.72                           | 0.92                            | 0.59                            | 11,217           |
| PRS<sub>SZ</sub>         | 0.25                            | 0.22                           | 0.42                            | 0.25                            | 2331             |
| JTC bias                | 0.51                            | 0.54                           | 0.61                            | 0.51                            | 8481             |
| Altered digit symbol    | 0.28                            | 0.39                           | 0.50                            | 0.29                            | 4144             |

**Discussion**

**Findings**

We found that of the total incidence of PE (around 1.4%), approximately 25% involved a combined phenotype of PE + NPD. Compared to PE-only, the combined phenotype was differentially characterised by perceived status gap, low social functioning, care use, antipsychotic use, childhood adversity, life events, family history, urbanicity and PRS-SZ, with additional suggestive differences for cannabis use and ethnic minority status—a pattern of results that is close to findings reported for psychotic disorder (Howes and Murray, 2014). We suggest that differential associations between PE-only and PE + NPD with various risk factors confirms social functioning, childhood trauma and PRS, and similar lack of significant discrimination between PE-only and PE + NPD for digit span (online Supplementary Table 6).
Table 3. Differential associations of incident PE, alone (PE-only) and in the context of NPD (PE + NPD), with demographic, clinical, aetiological and cognitive factors

| Binary exposure                  | PE-only |          |          |          | PE + NPD |          |          |
|----------------------------------|---------|----------|----------|----------|----------|----------|----------|
|                                  | HRa     | 95% CI   | P        | HR       | 95% CI   | P        |
| Young age group                  | 1.54    | 1.18     | 2.01     | 0.001    | 1.84     | 1.21     | 2.78     | 0.004    |
| Female sex                       | 1.27    | 1.04     | 1.56     | 0.019    | 1.37     | 0.98     | 1.93     | 0.069    |
| Perceived status gap             | 1.66    | 1.33     | 2.08     | 0.000    | 4.77*    | 3.43     | 6.64     | 0.000    |
| Low social functioning           | 1.40    | 1.15     | 1.71     | 0.001    | 6.21*    | 4.22     | 9.14     | 0.000    |
| Any care                         | 1.24    | 0.94     | 1.65     | 0.124    | 13.87*   | 9.83     | 19.58    | 0.000    |
| Mental health care               | 1.03    | 0.70     | 1.52     | 0.886    | 10.79*   | 7.73     | 15.05    | 0.000    |
| Antipsychotic use                | 2.73    | 1.02     | 7.31     | 0.046    | 16.98*   | 7.92     | 36.39    | 0.000    |
| Cannabis use                     | 1.82    | 0.58     | 5.67     | 0.302    | 10.36*   | 4.23     | 25.35    | 0.000    |
| Childhood adversity              | 1.66    | 1.32     | 2.08     | 0.000    | 3.92*    | 2.82     | 5.46     | 0.000    |
| Life events                      | 1.33    | 1.09     | 1.62     | 0.005    | 2.35*    | 1.66     | 3.34     | 0.000    |
| Ethnic minority                  | 1.29    | 0.90     | 1.84     | 0.166    | 2.33*    | 1.45     | 3.75     | 0.000    |
| Hearing impairment               | 2.07    | 1.34     | 3.18     | 0.001    | 1.96     | 0.96     | 4.00     | 0.065    |
| Urbanicity <16 years             | 0.85    | 0.69     | 1.04     | 0.113    | 1.54*    | 1.11     | 2.14     | 0.010    |
| Family history                   | 1.91    | 1.54     | 2.37     | 0.000    | 8.57*    | 4.74     | 15.48    | 0.000    |
| PRS-SZ                           | 0.80    | 0.56     | 1.13     | 0.204    | 2.47*    | 1.48     | 4.10     | 0.000    |
| JTC bias                         | 1.08    | 0.88     | 1.34     | 0.461    | 1.30     | 0.92     | 1.84     | 0.144    |
| Altered digit symbol             | 1.56    | 1.24     | 1.97     | 0.000    | 2.10     | 1.41     | 3.12     | 0.000    |

HR = hazard ratio, 95% CI = 95% confidence interval. Young age group: aged 18–35 years; Perceived status gap: difference between actual and desired social position; Low social functioning: SF-36 social functioning 75th percentile cut-off; Any care: any informal, medical or mental health care for mental problems or addiction; Cannabis use: once per week or more in the period of most frequent use; Childhood adversity: 80th percentile cut-off continuous score before age 16 years; Life events: at least one life event in the last year; Minority: Moroccan, Turkish, Surinamese, Antillean, Indonesian or other non-western ethnic group; Hearing impairment: T0 deafness or serious hearing impairment in the past 12 months; Urbanicity: 2 highest levels of 5-level urbanicity classification before age 16 years; Family history: family history mental disorder; PRS-SZ schizophrenia polygenic risk score 75th percentile cut-off; JTC: beads task decision 2 or less beads; Altered digit symbol: cut-off 75th percentile continuous score.

*HR significantly greater in PE + NPD group compared to PE-only group, based on non-overlapping confidence intervals.

Does PE-only reflect the risk for psychotic disorder?

The results indicate that 74% of the incidence of PE, namely the part not arising in combination with NPD is less likely to be of clinical relevance. Although the incidence of PE-only was not clinically neutral – as evidenced by some degree of association with most of the 17 factors under examination, these associations were (significantly) weaker as compared to PE + NPD and there was no association with health care use. These results concur with the previously documented suggestion that clinically relevant psychosis is an indicator of severity in the constellation of non-psychotic psychopathology, and should not be considered in isolation (van Os and Reininghaus, 2016; van Os and Guloksuz, 2017; Cupo et al., 2021).

The role of PRS and cognitive alterations

PRS-SZ was not associated with PE-only in terms of either direction or significance of association, whereas the PE + NPD phenotype was significantly and more strongly associated. It could be argued that this represents a chance finding imputable to impos-
with higher levels of environmental exposure, cognitive alterations may channel early states of non-psychotic psychopathology towards a poor outcome psychosis phenotype, whereas cognitive alterations in combination with low PRS-SZ may divert early psychopathology towards the more benign PE-only phenotype.

Implications for CHR-P/APS

These findings suggest a significant, genetically rooted discriminative function between the PE-only phenotype with relatively benign outcome and the more poor outcome PE + NPD phenotype. In the same direction, our evidence supports further investigation, in prospective CHR-P settings, of the hypothesis that non-psychotic psychopathology represents a necessary factor in the ontogenesis of psychotic disorders, such that the pathway from psychosis risk to clinical psychosis outcome requires a non-psychotic intermediary state, interacting with multiple conditions including cognitive alteration, high PRS-SZ and environmental exposure. Indeed, a recent follow-back study of a representative incidence sample confirmed this supposition (Cupo et al., 2021). Therefore, CHR-P/APS research should be reconceptualised from a focus on attenuated psychotic symptoms with exclusion of DSM-disorders, as the ‘pure’ representation of a supposedly homotypic psychosis risk state, towards a focus on poor-outcome NPDs, characterised by a degree of psychosis admixture, on the pathway to psychotic disorder outcomes (van Os and Reininghaus, 2016; Guloksuz et al., 2020; Cupo et al., 2021).

Methodological issues

The results should be interpreted in the context of a number of limitations. First, although the sample was sizeable, many participants were past the period of greatest risk for psychosis, reducing power. However, contrary to what is often thought, mean age of onset of psychotic disorder in the general population, not selected for age cut-off or poor outcome-related specific diagnostic criteria, is around 30 years for men and 40 years for women, replicated across different studies of treated incidence over extended periods in geographically defined areas (Castle et al., 1993; Allardycy et al., 2007). The relatively high incidence of psychosis outcomes in the current study confirms the age-related incidence pattern of psychosis. Second, although most important time-varying measures were dynamically captured over time, others were not. Thus, the measures of cognition were only assessed twice and modelled as a person-level average, not permitting dynamic modelling of incidence states of cognitive alterations, similar to the incidence states of NPD and PE.

Third, PRS-SZ was available for less than 50% of the sample, however this is unlikely to have biased the results given similar distributions of dependent and independent variables as a function of PRS-SZ availability. Finally, some of the comparisons between the states of PE-only and PE + NPD suffered from low power. For example, there were substantial effect size differences in the association with cannabis use and PRS-SZ, however the statistical resolution of these differences was limited. Similarly, even though the sample was relatively large and the follow-up extensive, the incidence of the outcome of interest, PE + NPD, was not high, occurring in 177 participants in the risk set of whom 142 counted as incident. As a result, confidence intervals sometimes were wide, particularly for rarer exposures.

Supplementary material. The supplementary material for this article can be found at https://doi.org/10.1017/S204579602100041X.

Data. The data on which this manuscript is based are not publicly available. However, data from NEMESIS-2 are available upon request. The Dutch ministry of health financed the data and the agreement is that these data can be

Fig. 1. Hazard ratio (HR) effect sizes of binary clinical, demographic, aetiological and cognitive factors in PE-only group relative to effect sizes of PE + NPD group (set at 100%, grey line). Young age group: aged 18–35 years; Perceived status gap: difference between actual and desired social position; Low social functioning: SF36 social functioning 75th percentile cut-off; Any care: any informal, medical or mental health care for mental problems or addiction; Cannabis use: once per week or more in the period of most frequent use; Childhood adversity: 80th percentile cut-off continuous adversity score before age 16 years; Life events: at least one life event in the last year; Minority: Moroccan, Turkish, Surinamese, Antillean, Indonesian or other non-western ethnic group; Hearing impairment: T0 deafness or serious hearing impairment in the past 12 months; Urbanicity: 2 highest levels of 5-level urbanicity classification before age 16 years; Family history: family history mental disorder; PRS-SZ: schizophrenia polygenic risk score 75th percentile cut-off; JTC: beads task decision 2 or less beads; Altered digit symbol: cut-off 75th percentile continuous score.
used freely under certain restrictions and always under supervision of the principal investigator (PI) of the study. Thus, some access restrictions do apply to the data. The PI of the study is the last author of this paper and can at all times be contacted to request data. At any time, researchers can contact the PI of NEMESIS-2 and submit a research plan, describing its background, research questions, variables to be used in the analyses, and an outline of the analyses. If a request for data sharing is approved, a written agreement will be signed stating that the data will only be used for addressing the agreed research questions described and not for other purposes.

**Acknowledgements.** None

**Financial support.** NEMESIS-2 is conducted by the Netherlands Institute of Mental Health and Addiction (Trimbos Institute) in Utrecht. Financial support has been received from the Ministry of Health, Welfare and Sport, with supplementary support from the Netherlands Organization for Health Research and Development (ZonMw). This work was supported by the supplementary support from the Netherlands Organization for Health and Mental Health and Addiction (Trimbos Institute) in Utrecht. Financial support.

**Conflict of interest.** Dr O’Donovan is supported by a collaborative research grant from Takeda Pharmaceuticals. Takeda played no part in the conception, design, implementation, funding or interpretation of this paper. No other disclosures were reported.

**References**

Ajnakina O, David AS and Murray RM (2018) ‘At risk mental state’ clinics for psychosis - an idea whose time has come - and gone! *Psychological Medicine* 49, 1–6.

Allardice J, McCreadie RG, Morrison G and van Os J (2007) Do symptom dimensions or categorical diagnoses best discriminate between known risk factors for psychosis? *Social Psychiatry and Psychiatric Epidemiology* 42, 429–437.

Bijl RV, Ravelli A and van Zessen G (1998) Prevalence of psychotic disorder in the general population: results of the Netherlands Mental Health Survey and Incidence Study (NEMESIS). *Social Psychiatry and Psychiatric Epidemiology* 33, 587–595.

Brugha T, Bebbington P, Tennant C and Hurry J (1985) The list of threatenings. *Social Psychiatry* 20, 307–309.

Castle DJ, Wessely S and Murray RM (1993) Sex and schizophrenia: effects of diagnostic stringency, and associations with and premorbid variables. *British Journal of Psychiatry* 162, 658–664.

Cupo L, McIlwaine SV, Daneault JG, Malla AK, Iyer SN, Jooberr R and Shah JL (2021) Timing, distribution, and relationship between nonpsychotic and subthreshold psychotic symptoms prior to emergence of a first episode of psychosis. *Schizophrenia Bulletin* 47, 604–614.

de Graaf R, Ten Have M and van Dorsselaer S (2010) The Netherlands mental health survey and incidence study-2 (NEMESIS-2): design and methods. *International Journal of Methods in Psychiatric Research* 19, 125–141.

Fusar-Poli P, Rutigliano G, Stahl D, Schmidt A, Ramella-Cravaro V, Hitesh S and McGuire P (2016) Deconstructing pretest risk enrichment to optimize prediction of psychosis in individuals at clinical high risk. *JAMA Psychiatry* 73, 1260–1267.

Fusar-Poli P, Salazar de Pablo G, Correll CU, Meyer-Lindenberg A, Millan MJ, Borgwardt S, Galderisi S, Bechdolf A, Pfennig A, Kessing LV, van Amelootso T, Nieman DH, Domshcke K, Krebs MO, Koutsoulis N, McGuire P, Do QK and Arango C (2020) Prevention of psychosis: advances in detection, prognosis, and intervention. *JAMA Psychiatry* 77, 755–765.

Grech A, Van Os J, Jones PB, Lewis SW and Murray RM (2005) Cannabis use and outcome of recent onset psychosis. *European Psychiatry* 20, 349–353.

Guloksuz S, Pries IK, Delespaul P, Kenis G, Luysy J, Lin BD, Richards AL, Akdede B, Binbay T, Altintayza V, Yalin cetin C, Gunus-Akay G, Cihan B, Soygur H, Ulas H, Cankurtaran E, Kaymak SU, Mihaljevic MM, Petrovic SA, Mirjanic T, Bernardo M, Cabrera B, Bobes J, Saiz PA, Garcia-Portilla MP, Sanjuan J, Aguilar E, Santos J, Jimenez-Lopez E, Arrojo M, Carracedo A, Lopez G, Gonzalez-Penas J, Parelada M, Marti NP, Athasos Lu C, Ucok A, Alptekin K, Saka MC, Arango C, O’Donovan M, Rutten BPF and van Os J (2019) Examining the independent and joint effects of molecular genetic liability and environmental exposures in schizophrenia: results from the EU-GEI study. *World Psychiatry* 18, 173–182.

Guloksuz S, Pries I, ten Have M, de Graaf R, van Dorselaer S, Klingenberg B, Bak M, Lin BD, van Eijk KR, Delespaul PAED, van Amelootso T, Luysy J, Rutten BPF and van Os J (2020) Association of preceding psychosis risk states and non-psychotic mental disorders with incidence of clinical psychosis in the general population: a prospective study in the NEMESIS-2 cohort. *World Psychiatry* 19, 199–205.

Gur RC, Calkins ME, Satterthwaite TD, Ruparel K, Bilker WB, Moore TM, Savitt AP, Hakonarson H and Gur RE (2014) Neurocognitive growth charting in psychosis spectrum youths. *JAMA Psychiatry* 71, 366–374.

Hafer H, Loffler W, Maurer K, Hambrecht M and an der Heiden W (1999) Depression, negative symptoms, social stagnation and social decline in the early course of schizophrenia. *Acta Psychiatratica Scandinavica*. 100, 105–118.

Hanssen M, Bak M, Bijl R, Vollebergh W and van Os J (2005) The incidence and outcome of subclinical psychotic experiences in the general population. *British Journal of Clinical Psychology* 44, 181–191.

Hatzimanolis A, Avramopoulos D, Arking DE, Moes A, Bhatnagar P, Lencz T, Malhotra AK, Giakoumaki SG, Roussos P, Smyrnis N, Bitsios P and Stefanis NC (2018) Stress-dependent association between polygenic risk for schizophrenia and schizotypal traits in young army recruits. *Schizophrenia Bulletin* 44, 338–347.

Hayes OD and Murray RM (2014) Schizophrenia: an integrated sociodevelopmental-cognitive model. *Lancet (London, England)* 383, 1677–1687.

Jeppesen P, Clemmensen L, Munkholm A, Rimvall MK, Rask CU, Jorgensen T, Larsen JT, Petersen L, van Os J and Skovgaard AM (2015) Psychotic experiences co-occur with sleep problems, negative affect and mental disorders in preadolescence. *Journal of Child Psychology and Psychiatry and Allied Disciplines* 56, 558–565.

Jonas KG, Lenz T, Li K, Malhotra AK, Perlman G, Fochtmann LJ, Bromet EJ and Kotow R (2019) Schizophrenia polygenic risk score and 20-year course of illness in psychotic disorders. *Translational Psychiatry* 9, 300.

Jones HJ, Stergioulis E, Tansey KE, Hubbard L, Heron J, Cannon M, Holmans P, Lewis G, Linden DEJ, Jones PB, Smith GD, O’Donovan MC, Owen MJ, Walters JT and Zammit S (2016) Phenotypic manifestation of genetic risk for schizophrenia during adolescence in the general population. *JAMA Psychiatry* Published online January 27, 2016.

Kaynaz N, van Os J, de Graaf R, Ten Have M, Nolen W and Krabbendam L (2007) The impact of subclinical psychosis on the transition from subclinical mania to bipolar disorder. *Journal of Affective Disorders* 98, 55–64.

Kaynaz N, Drukker M, Lieb R, Wittchen HU, Werbeloff N, Weiser M, Lataster T and van Os J (2012) Do subthreshold psychotic experiences predict clinical outcomes in unselected non-help-seeking population-based samples? A systematic review and meta-analysis, enriched with new results. *Psychological Medicine* 42, 2239–2253.

Koyanagi A, Stubbs B, Lara E, Veronese N, Vancampfort D, Smith L, Haro JM, Oh H and Devylder JE (2018) Psychotic experiences and subjective cognitive complaints among 224 842 people in 48 low- and middle-income countries. *Epidemiology and Psychiatric Sciences* 29, e11.

Kraan TC, Velthorst E, Themmen M, Valmaggia L, Kempton MJ, McGuire P, van Os J, Rutten BPF, Smit F, de Haan L, van der Gaag M and Study E-GHR (2018) Child maltreatment and clinical outcome in individuals at ultra-high risk for psychosis in the EU-GEI high risk study. *Schizophrenia Bulletin* 44, 584–592.

Guloksuz S, Pries I, ten Have M, de Graaf R, van Dorselaer S, Klingenberg B, Bak M, Lin BD, van Eijk KR, Delespaul PAED, van Amelootso T, Luysy J, Rutten BPF and van Os J
Legge SE, Jones HJ, Kendall KM, Pardinas AF, Menzies G, Bracher-Smith M, Escott-Price V, Rees E, Davis KAS, Hotopf M, Savage JE, Posthuma D, Holmes P, Kirov G, Owen MJ, O’Donovan MC, Zammit S and Walters JTR (2019) Association of genetic liability to psychotic experiences with neuropsychiatric disorders and traits. JAMA Psychiatry 76, 1256–1265.

Lin A, Wood SJ, Nelson B, Brewer WJ, Spiliotacopoulos D, Bruxner A, Broussard C, Pantelis C and Yung AR (2011) Neurocognitive predictors of functional outcome two to 13 years after identification as ultra-high risk for psychosis. Schizophrenia Research 132, 1–7.

Linscott RJ and van Os J (2013) An updated and conservative systematic review and meta-analysis of epidemiological evidence on psychotic experiences in children and adults: on the pathway from proneness to persistence to dimensional expression across mental disorders. Psychological Medicine 43, 1133–1149.

Moritz S, Gawaed L, Heinz A and Gallinat J (2019) Four reasons why early detection centers for psychosis should be renamed and their treatment targets re-considered: we should not catastrophize a future we can neither reliably predict nor change. Psychological Medicine, 2134–2140.

Niarcho M, Zammit S, Walters J, Lewis G, Owen MJ and van den Bree MB (2019) Genetic contribution to nonclinical psychotic experiences in children: longitudinal analyses in a large birth cohort. American Journal of Psychiatry 170, 550–557.

Pain O, Duabridge F, Cardno AG, Freeman D, Lu Y, Lundstrom S, Lichtenstein P and Ronald A (2018) Genome-wide analysis of adolescent psychotic-like experiences shows genetic overlap with psychiatric disorders. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics: The Official Publication of the International Society of Psychiatric Genetics 177, 416–425.

Planip-Illegor P, Pedersen CB, Holtz Y, Benros ME, Dalsgaard S, de Jonge P, Fan CC, Degenhardt L, Ganna A, Greve AN, Gunn J, Iburg KM, Kessing LV, Lee BK, Lim CCW, Mors O, Nordentoft M, Prior A, Roet AM, Saha S, Schork A, Scott JG, Scott KM, Stedman T, Soenssen HJ, Werge T, Whiteford HA, Laursen TM, Agerbo E, Kessler RC, Mortensen PB and McGrath JJ (2019) Exploring comorbidity within mental disorders among a Danish national population. JAMA Psychiatry 76, 259–270.

Pries LK, Guloksuz S, Ten Have M, de Graaf R, van Dorsselaer S, Gunther N, Rauschenberg C, Reininghaus U, Radhakrishnan R, Bak M, Rutten BPF and van Os J (2018) Evidence that environmental and familial risks for psychosis additively impact a multidimensional subthreshold psychosis syndrome. Schizophrenia Bulletin 44, 710–719.

Pries LK, Lager-Castellanos A, Delepaup P, Kenis G, Luykx JJ, Lin BD, Richards AL, Akedde B, Binbay T, Altinyazar V, Yalincetin B, Gumus-Akay G, Cihan B, Soygur H, Ulas H, Cankurtaran ES, Kaymak SU, Mihaljevic MM, Petrovic SA, Mirjanci T, Mendonca B, Cabrera B, Bobes J, Saiz PA, Garcia-Portilla MP, Sanjuan J, Aguilar EJ, Santos JL, Jimenez-Lopez E, Hansen M, Rauschenberg C, Reininghaus U, Radhakrishnan R, Bak M, Rutten BPF, van Os J and Guloksuz S (2019) Estimating exposure score for schizophrenia using predictive modeling approach in Two independent samples: the results from the EUGEI study. Schizophrenia Bulletin 45, 960–965.

Pries LK, ten Have M, de Graaf R, van Dorsselaer S, Gunther N, Bak M, Li BD, Luykx JJ, Rutten BPF and van Os J (2020) M126. The main and interactive effects of adult stressful life events with genomic and exposomic liability for schizophrenia on mental and physical health: a prospective cohort study. Schizophrenia Bulletin 46, S183–S183.

Rabalbo A and Poletti M (2019) Overlooking the transition elephant in the ultra-high-risk room: are we missing functional equivalents of transition to psychosis? Psychological Medicine, doi: 10.1017/S0033291719003337. Online ahead of print.

Radhakrishnan R, Guloksuz S, Ten Have M, de Graaf R, van Dorsselaer S, Gunther N, Rauschenberg C, Reininghaus U, Pries LK, Bak M and van Os J (2019) Interaction between environmental and familial affective risk impacts psychosis admixture in states of affective dysregulation. Psychological Medicine 49, 1879–1889.

Reininghaus U, Rauschenberg C, Ten Have M, de Graaf R, van Dorsselaer S, Simons CJP, Gunther N, Pries LK, Guloksuz S, Radhakrishnan R, Bak M and van Os J (2019) Reasoning bias, working memory performance and a transdiagnostic phenotype of affective disturbances and psychotic experiences in the general population. Psychological Medicine 49, 1799–1809.

Richards AL, Pardinas AF, Frizziati A, Tansey KE, Lynham AJ, Holmes P, Legge SE, Savage JE, Agartz I, Andreassen OA, Blokland GAM, Corvin A, Cosgrove D, Degenhardt F, Djurovic S, Espeseth T, Ferraro L, Gayer-Anderson C, Giegling I, van Haren NE, Hartmann AM, Hubert JJ, Jonsson EG, Korte B, Lennertz L, Olde Los Nhuis LM, Melle I, Morgan C, Morris DW, Murray RM, Nyman H, Ophoff RA, Investigators G, van Os J, Group EW, Schizophrenia Working Group of the Psychiatric Genomics C, Petersen TL, Quattrone D, Rietielsch M, Rujeusc D, Rutten BPF, Streit F, Stromhaier J, Sullivan PF, Sundet K, Wagner M, Escott-Price V, Owen MJ, Donohoe G, O’Donovan MC and Walters JTR (2020) The relationship between polygenic risk scores and cognition in schizophrenia. Schizophrenia Bulletin 46, 336–344.

Rossler W, Ajdacic-Gross V, Muller M, Rodgers S, Kavolw H, Haker H and Hengartner MP (2015) Association between processing speed and subclinical psychotic symptoms in the general population: focusing on sex differences. Schizophrenia Research 166, 316–321.

Rutiglano G, Valmaggia L, Landi P, Frascarelli M, Cappucciatii M, Sear Y, Rocchi M, De Micheli A, Jones C, Palombini E, McGuire P and Fusar-Poli P (2016) Persistence or recurrence of non-psychotic comorbid mental disorders associated with 6-year poor functional outcomes in patients at ultra high risk for psychosis. Journal of Affective Disorders 203, 101–110.

Salazar de Pablo G, Catalan A and Fusar-Poli P (2020) Clinical validity of DSM-5 attenuated psychosis syndrome: advances in diagnosis, prognosis, and treatment. JAMA Psychiatry 77, 311–320.

Schizophrenia Working Group of the Psychiatric Genomics Consortium (2014) Biological insights from 108 schizophrenia-associated loci. Nature 511, 421–427.

Shah JL, Tandon N, Montrose DM, Mermon D, Eack SM, Miewald J and Keshavan MS (2019) Clinical psychopathology in youth at familial high risk for psychosis. Early Intervention in Psychiatry 13, 297–303.

Smeets F, Lataster T, van Winkel R, de Graaf R, Ten Have M and van Os J (2013) Testing the hypothesis that psychotic illness begins when subthreshold hallucinations combine with delusional ideation. Acta Psychiatrisc Scandinavica 127, 34–47.

Stewart AL, Hays RD and Ware JE Jr. (1988) The MOS short-form general health survey. Reliability and validity in a patient population. Medical Care 26, 724–735.

Trotta A, Murray RM and Fisher HL (2015) The impact of childhood adversity on the persistence of psychotic symptoms: a systematic review and meta-analysis. Psychological Medicine, 45, 2481–2498.

Tsuang MT, Van Os J, Tandon R, Barch DM, Bustillo J, Gaebel W, Gur RE, Heckers S, Malaspina D, Owen MJ, Schultz S and Carpenter W (2013) Attenuated psychosis syndrome in DSM-5: Schizophrenia Research 150, 31–35.

van Nierop M, van Os J, Gunther N, Myin-Germeys I, de Graaf R, ten Have M, van Dorsselaer S, Bak M and van Winkel R (2012) Phenotypically continuous with clinical psychosis, discontinuous in need for care: evidence for an extended psychosis phenotype. Schizophrenia Bulletin 38, 231–238.

van Nierop M, Janssens M and Genetic Risk and Outcome of Psychosis (GROUP) Investigators (2013) Evidence that transition from health to psychotic disorder can be traced to semi-ubiquitous environmental effects operating against background genetic risk. PLoS ONE 8, e76090.

van Os J and Guloksuz S (2017) A critique of the “ultra-high-risk” and “transition” paradigm. World Psychiatry 16, 200–206.

van Os J and Reininghaus U (2016) Psychosis as a transdiagnostic and extended phenotype in the general population. World Psychiatry 15, 118–124.

Van Os J, Jones P, Sham P, Bebbington P and Murray RM (1998) Risk factors for onset and persistence of psychosis. Social Psychiatry and Psychiatric Epidemiology 33, 596–605.

Van Os J, Hanssen M, Bijl R and Ravelli A (2000) Strauss (1969) revisited: a psychosis continuum in the general population? Schizophrenia Research 45, 11–20.

van Os J, Pries LK, Delepaup P, Kenis G, Luykx JJ, Lin BD, Richards AL, Akedde B, Binbay T, Altinyazar V, Yalincetin B, Gumus-Akay G, Cihan B, Soygur H, Ulas H, Cankurtaran ES, Kaymak SU, Mihaljevic MM, Petrovic SA, Mirjanci T, Mendonca B, Cabrera B, Bobes J, Saiz PA, Garcia-Portilla MP, Sanjuan J, Aguilar EJ, Santos JL, Jimenez-Lopez E,
Arrojo M, Carracedo A, Lopez G, Gonzalez-Penas J, Parellada M, Maric NP, Ablasoglu C, Ucok A, Alptekin K, Saka MC, Genetic R, Outcome I, Arango C, O’Donovan M, Rutten BPF and Guloksuz S (2020) Replicated evidence that endophenotypic expression of schizophrenia polygenic risk is greater in healthy siblings of patients compared to controls, suggesting gene-environment interaction. The EUGEI study. Psychological Medicine 50, 1884–1897.

van Os J, Schaub A and Carpenter WT (2021) Resurrection of the follow-back method to study the transdiagnostic origins of psychosis. Schizophrenia Bulletin 47, 583–585.

van Rossum I, Dominguez MD, Lieb R, Wittchen HU and van Os J (2011) Affective dysregulation and reality distortion: a 10-year prospective study of their association and clinical relevance. Schizophrenia Bulletin 37, 561–571.

Ware JE Jr. and Sherbourne CD. (1992) The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Medical Care 30: 473–483.

Wechsler D. (1997) WAIS-III: Wechsler Adult Intelligence Scale (3rd Edn.) Administration and Scoring Manual, San Antonio, TX: Psychological Corporation.

Weiser M, Reichenberg A, Rabinowitz J, Kaplan Z, Mark M, Bodner E, Nahon D and Davidson M (2001) Association between nonpsychotic psychiatric diagnoses in adolescent males and subsequent onset of schizophrenia. Archives of General Psychiatry 58, 959–964.

Wigman JT, van Nierop M, Vollebergh WA, Lieb R, Beesdo-Baum K, Wittchen HU and van Os J (2012) Evidence that psychotic symptoms are prevalent in disorders of anxiety and depression, impacting on illness onset, risk, and severity – implications for diagnosis and ultra-high risk research. Schizophrenia Bulletin 38, 247–257.

Woods SW, Addington J, Cadenhead KS, Cannon TD, Cornblatt BA, Heinssen R, Perkins DO, Seidman LJ, Tsuang MT, Walker EF and McGlashan TH (2009) Validity of the prodromal risk syndrome for first psychotic: findings from the North American prodrome longitudinal study. Schizophrenia Bulletin 35, 894–908.